A new monoclonal antibody called nebokitug offers fresh hope to patients who have primary sclerosing cholangitis (PSC), ...

The global monoclonal antibody discovery platform market size is valued at USD 3.66 billion in 2025 and is predicted to hit ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Researchers have reported encouraging results from a clinical trial of a new monoclonal antibody therapy for primary ...

The latest announcement is out from Invivyd ( (IVVD) ).

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single ...

The recent safety review of two approved RSV preventive treatments for infants initiated by the U.S. Food and Drug ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole ...